MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday. Please watch the video at Investors.com - How To ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside.

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

Metsera (NASDAQ:MTSR) was able to complete its initial public offering [IPO] back on February 3rd of 2025. Before taking expenses into account, it was able to generate net proceeds of about $316.2 ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 programs in clinical development and its GPL-1 peptide has a ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage biotech breaking into the obesity market, the analyst ...

Cantor Fitzgerald initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an overweight rating on the stock.

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates. The bank highlighted Metsera's (NASDAQ:MTSR) long-acting GLP-1RA asset ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, ...